Blueprint Medicines Corp. (NASDAQ:BPMC)’s share price traded up 2.6% during trading on Friday . The stock traded as high as $20.76 and last traded at $20.65, with a volume of 78,684 shares. The stock had previously closed at $20.13.

Several equities analysts recently commented on the company. Cowen and Company reissued a “buy” rating on shares of Blueprint Medicines Corp. in a research report on Tuesday, May 10th. Zacks Investment Research lowered Blueprint Medicines Corp. from a “buy” rating to a “hold” rating in a research report on Wednesday, May 11th. Finally, Raymond James Financial Inc. assumed coverage on Blueprint Medicines Corp. in a research report on Friday, May 27th. They set an “outperform” rating and a $23.00 price target on the stock. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Blueprint Medicines Corp. presently has a consensus rating of “Buy” and a consensus price target of $28.50.

The firm’s market cap is $560.46 million. The stock has a 50 day moving average of $19.72 and a 200-day moving average of $18.14.

Blueprint Medicines Corp. (NASDAQ:BPMC) last posted its quarterly earnings results on Tuesday, May 10th. The company reported ($0.57) earnings per share for the quarter, beating the consensus estimate of ($0.70) by $0.13. The business had revenue of $6.90 million for the quarter, compared to analyst estimates of $3.24 million. Blueprint Medicines Corp.’s revenue for the quarter was up 961.5% compared to the same quarter last year. Analysts anticipate that Blueprint Medicines Corp. will post ($3.10) earnings per share for the current fiscal year.

In related news, CEO Jeffrey W. Albers sold 17,000 shares of the company’s stock in a transaction on Friday, June 3rd. The stock was sold at an average price of $20.03, for a total transaction of $340,510.00. Following the transaction, the chief executive officer now directly owns 92,486 shares of the company’s stock, valued at $1,852,494.58. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. The Company focuses on crafting drug candidates with therapeutic windows that provide clinical responses to patients without adequate treatment options.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.